Following recent changes to the Guidelines for Disinfectants under Therapeutic Goods Order 104, which allow listed disinfectants to make validated claims to kill the SARS-CoV-2 (COVID-19) virus on surfaces, VIRACLEAN®—manufactured by the Whiteley Corporation—has the first newly approved label claim for killing the SARS-CoV-2 (COVID-19) virus on contaminated surfaces.
Viraclean® is a hospital-grade disinfectant intended for use on a wide range of surfaces which may be contaminated, better protecting patients and staff from the risk of SARS-CoV-2 (COVID-19) virus cross infection. (It is important to note that the product is a surface disinfectant and not intended for use directly on people, or for treating a patient.)
Given the capacity of COVID-19 to survive on hard and relatively soft surfaces for a prolonged period of time, cleaning and disinfecting those surfaces is incredibly important to limiting the spread of the virus.
“This new label claim for Viraclean® against the virus responsible for the current pandemic will add to certainty around the level of hygiene in hospitals, particularly in intensive care units, emergency departments, and a range of other clinical, medical and dental applications,” Whiteley Corporation chairman Dr Greg Whiteley said.
“These claims will also be applied to INSTRUMAX® PINK, which is used for disinfection of non-critical medical devices in the hospital and healthcare sector.”
This article was sourced from the ADA website.
